Can a single graduate program in the US cover both venture capital and pharmaceutical law for life sciences professionals?

These are two very different directions, and no single program fully addresses both with equal depth, but some come closer than others. For venture capital, an MBA gives you the network, dealflow access, and resources most relevant to the asset class. You can also enter VC through angel investing without a degree at all, by beginning to deploy capital now and building a track record. For pharmaceutical law, understanding drug launch liability, clinical trial bylaws, what happens if a patient sues during a trial, most generalist MBA programs cover this only lightly, through one or two ethics and corporate accountability modules.

• Programs designed specifically for life sciences go meaningfully deeper.
• The Harvard MS-MBA in Life Sciences includes policy and regulatory content that touches on these areas.
• The Johns Hopkins Masters in Biotechnology Enterprise and Entrepreneurship covers law and ethics as a dedicated module.
• If the legal dimension of drug launches is a genuine priority rather than background knowledge, these life sciences-specific programs are the better fit.